Award of a contract to an independent scientific institution to accompany and evaluate the testing of microvascular reperfusion of myocardial tissue by means of intracoronary hyperoxemic therapy (SSO2 therapy) after primary percutaneous coronary intervention in acute anterior wall infarction

The purpose of the trial is to answer the question of whether microvascular reperfusion of myocardial tissue by means of SSO2-

Primary percutaneous coronary intervention (pPCI) therapy is superior to primary percutaneous coronary intervention alone in terms of all-cause mortality and unplanned heart failure-related hospitalizations after at least 12 months.